Multi-agent Low Dose Chemotherapy (Gemcitabine, Nab-paclitaxel, Capecitabine, Cisplatin, Irinotecan) Followed by Maintenance Olaparib and Pembrolizumab in Untreated Metastatic Pancreatic Ductal Adenocarcinoma
Summary
The purpose of this phase II trial is to evaluate the safety and efficacy of maintenance olaparib and pembrolizumab following multi agent, low dose chemotherapy with gemcitabine, nab-paclitaxel, capecitabine, cisplatin, and irinotecan in patients with untreated metastatic adenocarcinoma.
General Information
NCT#: NCT04753879
Study ID: J2112
Trial Phase: Phase II
Trial Sponsor: Merck Sharp & Dohme Corp., Sidney Kimmel Comprehensive Cancer Center
Therapies Used in This Trial: Nab-paclitaxel, Gemcitabine, Capecitabine, Irinotecan, Cisplatin, Olaparib, Pembrolizumab